Context Therapeutics doses first patient in Phase 1 trial of CT-202 bispecific antibody
CNTX•Trial objectives
The trial aims to assess safety and tolerability, gauge drug behavior in the body, and look for early signs of anti-tumor activity.
First patient dosed in CT-202 Phase 1 trial
Context Therapeutics dosed the first patient in a Phase 1 trial of CT-202, a Nectin-4 x CD3 bispecific antibody for solid tumors.
The study is testing CT-202 as a monotherapy in refractory or resistant Nectin-4-expressing cancers, including urothelial, colorectal, and triple-negative breast cancer.
No clinical results have been presented; initial Phase 1a data are expected in the second half of 2027.
